Gligor Vasile
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gligor Vasile has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Boicean
Faculty of Medicine, Lucian Blaga University of Sibiu, 550169 Sibiu, Romania
1 shared publication - Adrian Hașegan
Faculty of Medicine, “Lucian Blaga” University of Sibiu, 550024 Sibiu, Romania
1 shared publication - Ciprian Bacila
Faculty of Medicine, Lucian Blaga University of Sibiu, 550024 Sibiu, Romania
1 shared publication - Dan Georgian Bratu
Faculty of Medicine, Lucian Blaga University of Sibiu, 550169 Sibiu, Romania
1 shared publication - Leeb Shelly
County Clinical Emergency Hospital of Sibiu, 550245 Sibiu, Romania
1 shared publication - Sabrina Birsan
Faculty of Medicine, University Lucian Blaga, 550024 Sibiu, Romania
1 shared publication
Latest Publications
- Open Access
Exploring the Potential of Fecal Microbiota Transplantation as a Therapy in Tuberculosis and Inflammatory Bowel Disease
This review explores the potential benefits of fecal microbiota transplantation (FMT) as an adjunct treatment in tuberculosis (TB), drawing parallels from its efficacy in inflammatory bowel disease (IBD). FMT has shown promise in restoring the gut microbial balance and modulating immune responses in IBD patients. Considering the similarities in immunomodulation and dysbiosis between IBD and TB, this review hypothesizes that FMT may offer therapeutic benefits as an adjunct therapy in TB. Methods: We conducted a systematic review of the existing literature on FMT in IBD and TB, highlighting the mechanisms and potential implications of FMT in the therapeutic management of both conditions. The findings contribute to understanding FMT’s potential role in TB treatment and underscore the necessity for future research in this direction to fully leverage its clinical applications. Conclusion: The integration of FMT into the comprehensive management of TB could potentially enhance treatment outcomes, reduce drug resistance, and mitigate the side effects of conventional therapies. Future research endeavors should focus on well-designed clinical trials to develop guidelines concerning the safety and short- and long-term benefits of FMT in TB patients, as well as to assess potential risks.
Open AccessExploring the Potential of Fecal Microbiota Transplantation as a Therapy in Tuberculosis and Inflammatory Bowel Disease
This review explores the potential benefits of fecal microbiota transplantation (FMT) as an adjunct treatment in tuberculosis (TB), drawing parallels from its efficacy in inflammatory bowel disease (IBD). FMT has shown promise in restoring the gut microbial balance and modulating immune responses in IBD patients. Considering the similarities in immunomodulation and dysbiosis between IBD and TB, this review hypothesizes that FMT may offer therapeutic benefits as an adjunct therapy in TB. Methods: We conducted a systematic review of the existing literature on FMT in IBD and TB, highlighting the mechanisms and potential implications of FMT in the therapeutic management of both conditions. The findings contribute to understanding FMT’s potential role in TB treatment and underscore the necessity for future research in this direction to fully leverage its clinical applications. Conclusion: The integration of FMT into the comprehensive management of TB could potentially enhance treatment outcomes, reduce drug resistance, and mitigate the side effects of conventional therapies. Future research endeavors should focus on well-designed clinical trials to develop guidelines concerning the safety and short- and long-term benefits of FMT in TB patients, as well as to assess potential risks.